Executive Summary of the SEPAR Recommendations for the Diagnosis and Treatment of Non-small Cell Lung Cancer

Álvarez, Felipe Villar; Trueba, Ignacio Muguruza; Sanchis, José Belda; López-Rodó, Laureano Molins; Suárez, José P.; Escuín, Julio Sánchez de Cos; Barreiro, Esther; Pintado, M. Henar Borrego; Vicente, Carlos Disdier; Aldeyturriaga, Javier Flandes; Garcı́a, Pablo Gámez; López, P. Garrido; Atance, Pablo León; Elena, José Miguel Izquierdo; Novoa, Nuria; Andrés, Juan José Rivas de; Crespo, Iñigo.; Velázquez, Ángel Salvatierra; Maceiras, Luís M. Seijo; Reina, Segismundo Solano; Bujanda, David Aguiar; Martínez, Régulo José Ávila; Orive, José Ignacio de Granda; Martínez, Eva de Higes; Gude, V. Díaz-Hellín; Flor, Raúl Embún; Gilart, Jorge L. Freixinet; Jiménez, María Dolores García; Alarza, Fátima Hermoso; Sarmiento, Samuel; Martínez, Antonio Francisco Honguero; Ruiz, Carlos A. Jiménez; Sanz, Iker López; Alba, Andrea Mariscal de; Vallina, Primitivo Martínez; Muñoz, Patricia Menal; Pérez, Laura Mezquita; Garcia, Maria Eugenia Olmedo; Rombolá, Carlos A.; Arregui, Íñigo San Miguel; Gutiérrez, María de Valle Somiedo; Ramírez, Ana Isabel Triviño; Reyes, Joan Carles Trujillo; Vallejo, Carmen; Lozano, Paz Vaquero; Simó, Gonzalo Varela; Zulueta, Javier

doi:10.1016/j.arbr.2016.02.020

Cited by 19 publications

(12 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this regard, a useful genetic marker should: (I) be implicated in the tumorigenesis (such as driver alterations) because the pathway suppression could control tumor proliferation; (II) have a high prevalence, to justify the benefit of a costly test; (III) have a highly sensitive and specific validated test; and (IV) have a previously designated oncogenic pathway, with an already available targeted therapy. Although some years ago, a panel of experts from IASLC, ATS and ERS recommended molecular testing only for the EGFR mutation in advanced ADC, more recent recommendations also include EML4-ALK rearrangement in advanced-stages of lung ADC (either locally advanced or metastatic cancer) (95). However, the latest advances in molecular profiling and guided therapies strongly suggest that the screening should already be extended to at least detection of ROS1 fusions, BRAF mutations and MET amplifications or exon 14 alterations, performing a wider genomic profiling in any stage of ADC (26,64,96,97).…”

Section: Ros1 Translocationsmentioning

confidence: 99%

Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy

et al. 2017

View full text Add to dashboard Cite

Although adenocarcinoma (ADC) is the most frequent lung cancer, its diagnosis is often late, when the local invasion is important and/or the metastases have already appeared. Therefore, the mortality at 5 years is still very high, ranging from 51% to 99%, depending on the stage. The implementation of different molecular techniques has allowed genomic studies even in relatively small histological samples such as obtained with non-invasive or minimally invasive techniques, facilitating a better phenotyping of lung ADC. Thus, current classification differentiates between preinvasive lesions (atypical adenomatous hyperplasia and in situ ADC), minimally invasive ADC (MIA) and invasive ADC. 'Field cancerization' is a concept that refers to progressive loco-regional changes occurring in tissues exposed to carcinogens, due to the interaction of the latter with a predisposing genetic background and an appropriate tissue microenvironment. Somatic genetic alterations, including mutations but also other changes, are necessary for oncogenesis, being especially frequent in lung ADC. Changes in the epidermal growth factor receptor () gene, Kirsten rat sarcoma viral oncogene (), v-Raf murine sarcoma viral oncogene homolog B (), gene encoding neurofibromin (), anaplastic lymphoma kinase () and are the main genes that suffer alterations in the tumors of patients with ADC. Molecular profiling of these tumors allows more targeted treatments through two distinct strategies, genome-guided therapy and immunotherapy. The former, targets the aberrant pathways secondary to the genomic alteration, whereas the latter may be based on the administration of antibodies [such as those against cytotoxic T-lymphocyte antigen 4 (CTLA-4) or the programmed cell death ligand 1/protein 1 pathway (PD-L1/PD-1)] or the stimulation of the patient's own immune system to produce a specific response. These strategies are obtaining better results in selected ADC patients.

show abstract

Section: Ros1 Translocationsmentioning

confidence: 99%

Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Si se constata la presencia de mutaciones de susceptibilidad en el EGFR la primera línea de tratamiento serán los ITK. Este es el esquema de tratamiento con el que se está tratando a nuestro paciente 7,8 .…”

Section: Discusión Y Conclusiónunclassified

Adenocarcinoma de pulmón con patrón de crecimiento lepídico

Etxeberria-Lekuona¹,

Iridoy-Zulet²

2020

Rev Esp Casos Clin Med Intern

View full text Add to dashboard Cite

El adenocarcinoma de pulmón es un tipo de cáncer caracterizado por la existencia de múltiples subtipos histológicos con una gran variedad de manifestaciones clínicas y radiológicas. Varios de ellos presentan un característico crecimiento lepídico sobre la superficie alveolar que no invade las estructuras subyacentes. Presentamos el caso de un paciente de 60 años con un debut clínico compatible con una neumonía multi- lobar. Después del ingreso hospitalario se llegó al diagnóstico de un adenocarcinoma pulmonar de patrón lepídico. El paciente recibió tratamiento oncológico con fármacos inhibidores de la tirosina-quinasa en base a la farmacogenética del tumor.

show abstract

“…It has also been commonly used as a nutraceutical in both human and animal models [ 20 ]. In several species, resveratrol also increased lifespan, probably through prevention of processes such as redox imbalance, inflammation, obesity, diabetes, and atherosclerosis [ 21 , 22 , 23 , 24 ]. In skeletal muscles, resveratrol was shown to reduce injury of gastrocnemius in rats [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

Beneficial Effects of Resveratrol in Mouse Gastrocnemius: A Hint to Muscle Phenotype and Proteolysis

Mañas-García

Denhard

Mateu

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

We hypothesized that the phenolic compound resveratrol mitigates muscle protein degradation and loss and improves muscle fiber cross-sectional area (CSA) in gastrocnemius of mice exposed to unloading (7dI). In gastrocnemius of mice (female C57BL/6J, 10 weeks) exposed to a seven-day period of hindlimb immobilization with/without resveratrol treatment, markers of muscle proteolysis (tyrosine release, systemic troponin-I), atrophy signaling pathways, and muscle phenotypic features and function were analyzed. In gastrocnemius of unloaded mice treated with resveratrol, body and muscle weight and function were attenuated, whereas muscle proteolysis (tyrosine release), proteolytic and apoptotic markers, atrophy signaling pathways, and myofiber CSA significantly improved. Resveratrol treatment of mice exposed to a seven-day period of unloading prevented body and muscle weight and limb strength loss, while an improvement in muscle proteolysis, proteolytic markers, atrophy signaling pathways, apoptosis, and muscle fiber CSA was observed in the gastrocnemius muscle. These findings may have potential therapeutic implications in the management of disuse muscle atrophy in clinical settings.

show abstract

Executive Summary of the SEPAR Recommendations for the Diagnosis and Treatment of Non-small Cell Lung Cancer

Cited by 19 publications

References 94 publications

Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy

Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy

Adenocarcinoma de pulmón con patrón de crecimiento lepídico

Beneficial Effects of Resveratrol in Mouse Gastrocnemius: A Hint to Muscle Phenotype and Proteolysis

Contact Info

Product

Resources

About